10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

CHFR Antibody (C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP14431b

Product Information

Application	WB, E
Primary Accession	Q96EP1
Other Accession	Q810L3, NP_001154818.1, NP_001154817.1
Reactivity	Human
Predicted	Mouse, Rat, Bovine, Canine, Rabbit, Chicken
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB34596
Calculated MW	73386
Antigen Region	476-504

Additional Information

Gene ID	55743
Other Names	E3 ubiquitin-protein ligase CHFR, 632-, Checkpoint with forkhead and RING finger domains protein, RING finger protein 196, CHFR, RNF196
Target/Specificity	This CHFR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 476-504 amino acids from the C-terminal region of human CHFR.
Dilution	WB~~1:1000 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	CHFR Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	CHFR
Synonyms	RNF196

Function	E3 ubiquitin-protein ligase that functions in the antephase checkpoint by actively delaying passage into mitosis in response to microtubule poisons. Acts in early prophase before chromosome condensation, when the centrosome move apart from each other along the periphery of the nucleus. Probably involved in signaling the presence of mitotic stress caused by microtubule poisons by mediating the 'Lys- 48'-linked ubiquitination of target proteins, leading to their degradation by the proteasome. Promotes the ubiquitination and subsequent degradation of AURKA and PLK1. Probably acts as a tumor suppressor, possibly by mediating the polyubiquitination of HDAC1, leading to its degradation. May also promote the formation of 'Lys-63'- linked polyubiquitin chains and functions with the specific ubiquitin-conjugating UBC13-MMS2 (UBE2N-UBE2V2) heterodimer. Substrates that are polyubiquitinated at 'Lys-63' are usually not targeted for degradation, but are rather involved in signaling cellular stress.
Cellular Location	Nucleus, PML body
Tissue Location	Ubiquitous..


Background

E3 ubiquitin-protein ligase that functions in the antephase checkpoint by actively delaying passage into mitosis in response to microtubule poisons. Acts in early prophase before chromosome condensation, when the centrosome move apart from each other along the periphery of the nucleus. Probably involved in signaling the presence of mitotic stress caused by microtubule poisons by mediating the 'Lys-48'-linked ubiquitination of target proteins, leading to their degradation by the proteasome. Promotes the ubiquitination and subsequent degradation of AURKA and PLK1. Probably acts as a tumor suppressor, possibly by mediating the polyubiquitination of HDAC1, leading to its degradation. May also promote the formation of 'Lys-63'-linked polyubiquitin chains and functions with the specific ubiquitin-conjugating UBC13-MMS2 (UBE2N-UBE2V2) heterodimer. Substrates that are polyubiquitinated at 'Lys-63' are usually not targeted for degradation, but are rather involved in signaling cellular stress.

References

Soutto, M., et al. Cancer 116(17):4033-4042(2010)
Kim, J.M., et al. Biochem. Biophys. Res. Commun. 395(4):515-520(2010)
Hiraki, M., et al. World J. Gastroenterol. 16(3):330-338(2010)
Baba, S., et al. Oncol. Rep. 22(5):1173-1179(2009)
Gao, Y., et al. Int. J. Biol. Markers 24(2):83-89(2009)

Images



CHFR Antibody (C-term) (Cat. #AP14431b) western blot analysis in A549 cell line lysates (35ug/lane).This demonstrates the CHFR antibody detected the CHFR protein (arrow).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.